OSCR · Oscar Health, Inc.
$30.07
-1.17 (-3.75%)
At close · Aug 27
Market Cap
$9.62B
Shares
308.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.24
Open$30.59
Day$30.30–32.59
52W close$10.85–32.76
Avg vol 30d5.4M
Short int16.4M · 5.3% float · 2.3d
Short vol34%
Last earningsAug 6, 2026
DataMar 2021–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+57%
above
Price vs 50-day avg
+4%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
93%
near high
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+117%
trailing
YTD return
+117%
this year
Relative strength
+105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +127 funds added
Insider flow
Distributing
Net -$595.1K over 90 days · 100% sells
Short interest
Falling
5.33% of float · ▼ -7.8% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
407 holders — near 3-yr high, broad support
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+28%
Y/Y
EPS growth
−1790%
Y/Y
Valuation
P/E 21.5
below peers
Balance sheet
$2.3B
net cash
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Medical Loss Ratio
· Full Year 2026
Initiated
81.5% – 82.5%
SG&A Expense Ratio
· Full Year 2026
Maintained
15.6% – 16.1%
Jun 30, 2026
15.6% – 16.1%
changed to
Aug 6, 2026
15.6% – 16.1%
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total Revenue
· Full Year 2025 Outlook
$12B – $12.2B
Medical Loss Ratio
· Full Year 2025 Outlook
86% – 87%
SG&A Expense Ratio
· Full Year 2025 Outlook
17.1% – 17.6%
Loss from Operations
· Full Year 2025 Outlook
$-300M – $-200M
Guided vs delivered
· last 2 settled
Total Revenue
Full Year 2025 Outlook
guided $12B – $12.2B
$11.7B
Miss −3.3%
Total revenues
2024 full year
guided $8.3B – $8.4B
$9.18B
Beat +9.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+57%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $30 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +127 funds added
Insider flow
Distributing
Net -$595.1K over 90 days · 100% sells
Short interest
Falling
5.33% of float · ▼ -7.8% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
407 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $31 · 93%
Range high $33
vs 200-day avg +57%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Selling, general, and administrative ("SG&A") expense ratio | 14.2% | the three months ended June 30, 2026 filing | — |
|
|
|||
| Adjusted EBITDA non-GAAP | 1.14B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Medical Loss Ratio | 75% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Individual and Small Group | 3,174,489 | As of March 31, 2026 | — |
| Total Members | 3,174,489 | As of March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OSCR
this stock
Oscar Health, Inc.
|
$9.62B | +117.4% | +27.5% | 21.5 | 5.3% |
|
UNH
Unitedhealth Group Inc
|
$359.94B | +21.5% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$119.49B | +18.9% | +7.8% | 24.7 | 1.3% |
|
ELV
Elevance Health, Inc.
|
$86.55B | +14.8% | +12.5% | 17.7 | 2.5% |
|
CI
Cigna Group
|
$74.06B | +2.0% | +11.2% | 11.6 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OSCR | -3.3% | +2.2% | +117.1% | +0.1% | +117.4% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -2.9% | -2.8% | +104.7% | -2.5% | +105.1% |
Key facts
CIK
1568651
CUSIP
687793109
13F (30d)
338 filings
337 filers
Visit website
Investor relations